TY - JOUR AU - Gladman, D. D. AU - Antoni, C. AU - Mease, P. PY - 2005 DA - 2005// TI - Psoriatic arthritis: epidemiology, clinical features, course, and outcome JO - Ann Rheum Dis VL - 64 ID - Gladman2005 ER - TY - JOUR AU - Germano, V. AU - Cattaruzza, M. S. AU - Osborn, J. PY - 2014 DA - 2014// TI - Infection risk in rheumatoid arthritis and spondyloarthropathy patients under treatment with DMARDs, corticosteroids and TNF-α antagonists JO - J Transl Med VL - 12 UR - https://doi.org/10.1186/1479-5876-12-77 DO - 10.1186/1479-5876-12-77 ID - Germano2014 ER - TY - JOUR AU - Ritchlin, C. T. AU - Colbert, R. A. AU - Gladman, D. D. PY - 2017 DA - 2017// TI - Psoriatic arthritis JO - N Engl J Med VL - 376 UR - https://doi.org/10.1056/NEJMra1505557 DO - 10.1056/NEJMra1505557 ID - Ritchlin2017 ER - TY - JOUR AU - Garcia-Doval, I. AU - Cohen, A. D. AU - Cazzaniga, S. PY - 2017 DA - 2017// TI - Psonet Network. Risk of serious infections, cutaneous bacterial infections, and granulomatous infections in patients with psoriasis treated with anti-tumor necrosis factor agents versus classic therapies: Prospective meta-analysis of Psonet registries JO - J Am Acad Dermatol VL - 76 UR - https://doi.org/10.1016/j.jaad.2016.07.039 DO - 10.1016/j.jaad.2016.07.039 ID - Garcia-Doval2017 ER - TY - STD TI - Dávila-Seijo P, Dauden E, Descalzo MA, et al. BIOBADADERM Study Group. Infections in moderate to severe psoriasis patients treated with biological drugs compared to classic systemic drugs: findings from the BIOBADADERM registry. J Invest Dermatol. 2017;137:313–21. ID - ref5 ER - TY - JOUR AU - Yiu, Z. Z. AU - Exton, L. S. AU - Jabbar-Lopez, Z. PY - 2016 DA - 2016// TI - Risk of serious infections in patients with psoriasis on biologic therapies: a systematic review and meta-analysis JO - J Invest Dermatol VL - 136 UR - https://doi.org/10.1016/j.jid.2016.03.035 DO - 10.1016/j.jid.2016.03.035 ID - Yiu2016 ER - TY - JOUR AU - Kalb, R. o. b. e. r. t. E. AU - Fiorentino, D. a. v. i. d. F. AU - Lebwohl, M. a. r. k. G. AU - Toole, J. o. h. n. AU - Poulin, Y. v. e. s. AU - Cohen, A. r. n. o. n. D. AU - Goyal, K. a. v. i. t. h. a. AU - Fakharzadeh, S. t. e. v. e. n. AU - Calabro, S. t. e. p. h. e. n. AU - Chevrier, M. a. r. c. AU - Langholff, W. a. y. n. e. AU - You, Y. i. n. AU - Leonardi, C. r. a. i. g. L. PY - 2015 DA - 2015// TI - Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis JO - JAMA Dermatology VL - 151 UR - https://doi.org/10.1001/jamadermatol.2015.0718 DO - 10.1001/jamadermatol.2015.0718 ID - Kalb2015 ER - TY - JOUR AU - Minozzi, S. AU - Bonovas, S. AU - Lytras, T. PY - 2016 DA - 2016// TI - Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis JO - Expert Opin Drug Saf VL - 15 UR - https://doi.org/10.1080/14740338.2016.1240783 DO - 10.1080/14740338.2016.1240783 ID - Minozzi2016 ER - TY - JOUR AU - Accortt, N. A. AU - Bonafede, M. M. AU - Collier, D. H. PY - 2016 DA - 2016// TI - Risk of subsequent infection among patients receiving tumor necrosis factor inhibitors and other disease-modifying antirheumatic drugs JO - Arthritis Rheumatol VL - 68 UR - https://doi.org/10.1002/art.39416 DO - 10.1002/art.39416 ID - Accortt2016 ER - TY - JOUR AU - Singh, J. A. AU - Cameron, C. AU - Noorbaloochi, S. PY - 2015 DA - 2015// TI - Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis JO - Lancet. VL - 386 UR - https://doi.org/10.1016/S0140-6736(14)61704-9 DO - 10.1016/S0140-6736(14)61704-9 ID - Singh2015 ER - TY - JOUR AU - Subesinghe, S. u. j. i. t. h. AU - Rutherford, A. n. d. r. e. w. I. a. n. AU - Byng-Maddick, R. a. c. h. e. l. AU - Leanne Hyrich, K. i. m. m. e. AU - Benjamin Galloway, J. a. m. e. s. PY - 2018 DA - 2018// TI - Recurrent serious infections in patients with rheumatoid arthritis—results from the British Society for Rheumatology Biologics Register JO - Rheumatology VL - 57 UR - https://doi.org/10.1093/rheumatology/kex469 DO - 10.1093/rheumatology/kex469 ID - Subesinghe2018 ER - TY - JOUR AU - Richter, A. AU - Listing, J. AU - Schneider, M. PY - 2016 DA - 2016// TI - Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis JO - Ann Rheum Dis VL - 75 UR - https://doi.org/10.1136/annrheumdis-2015-207838 DO - 10.1136/annrheumdis-2015-207838 ID - Richter2016 ER - TY - JOUR AU - Haddad, A. AU - Li, S. AU - Thavaneswaran, A. PY - 2016 DA - 2016// TI - The incidence and predictors of infection in psoriasis and psoriatic arthritis: results from longitudinal observational cohorts JO - J Rheumatol VL - 43 UR - https://doi.org/10.3899/jrheum.140067 DO - 10.3899/jrheum.140067 ID - Haddad2016 ER - TY - JOUR AU - Pérez-Plaza, A. AU - Carretero, G. AU - Ferrandiz, C. AU - Vanaclocha, F. AU - Gómez-García, F. J. AU - Herrera-Ceballos, E. AU - De la Cueva-Dobao, P. AU - Belinchón, I. AU - Sánchez-Carazo, J. L. AU - Alsina, M. AU - López-Estebaranz, J. L. AU - Ferrán, M. AU - Torrado, R. AU - Carrascosa, J. M. AU - Llamas-Velasco, M. AU - Rivera, R. AU - Jiménez-Puya, R. AU - García-Doval, I. AU - Descalzo, M. A. PY - 2017 DA - 2017// TI - Comparison of phenotype, comorbidities, therapy and adverse events between psoriatic patients with and without psoriatic arthritis. Biobadaderm registry JO - Journal of the European Academy of Dermatology and Venereology VL - 31 UR - https://doi.org/10.1111/jdv.14188 DO - 10.1111/jdv.14188 ID - Pérez-Plaza2017 ER - TY - JOUR AU - Ramiro, S. AU - Gaujoux-Viala, C. AU - Nam, J. L. PY - 2014 DA - 2014// TI - Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis JO - Ann Rheum Dis VL - 73 UR - https://doi.org/10.1136/annrheumdis-2013-204575 DO - 10.1136/annrheumdis-2013-204575 ID - Ramiro2014 ER - TY - JOUR AU - Galloway, J. B. AU - Hyrich, K. L. AU - Mercer, L. K. PY - 2011 DA - 2011// TI - BSRBR Control Centre Consortium; British Society for Rheumatology Biologics Register. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly JO - Rheumatology (Oxford) VL - 50 UR - https://doi.org/10.1093/rheumatology/keq242 DO - 10.1093/rheumatology/keq242 ID - Galloway2011 ER - TY - JOUR AU - Dommasch, E. D. AU - Abuabara, K. AU - Shin, D. B. PY - 2011 DA - 2011// TI - The risk of infection and malignancy with tumor necrosis factor antagonists in adult patients with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials JO - J Am Acad Dermatol VL - 64 UR - https://doi.org/10.1016/j.jaad.2010.09.734 DO - 10.1016/j.jaad.2010.09.734 ID - Dommasch2011 ER - TY - JOUR AU - Papp, K. A. AU - Strober, B. AU - Augustin, M. PY - 2012 DA - 2012// TI - PSOLAR investigators and steering committee. PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents JO - J Drugs Dermatol VL - 11 ID - Papp2012 ER - TY - JOUR AU - Gottlieb, A. B. AU - Kalb, R. E. AU - Langley, R. G. PY - 2014 DA - 2014// TI - Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapies JO - J Drugs Dermatol. VL - 13 ID - Gottlieb2014 ER - TY - JOUR AU - Kavanaugh, A. AU - Papp, K. AU - Gottlieb, A. B. PY - 2018 DA - 2018// TI - Demography, baseline disease characteristics, and treatment history of psoriasis patients with self-reported psoriatic arthritis enrolled in the PSOLAR registry JO - BMC Rheumatology VL - 2 UR - https://doi.org/10.1186/s41927-018-0034-7 DO - 10.1186/s41927-018-0034-7 ID - Kavanaugh2018 ER - TY - JOUR AU - Dixon, W. G. AU - Watson, K. AU - Lunt, M. AU - Hyrich, K. L. AU - Silman, A. J. AU - Symmons, D. P. M. PY - 2006 DA - 2006// TI - Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register JO - Arthritis & Rheumatism VL - 54 UR - https://doi.org/10.1002/art.21978 DO - 10.1002/art.21978 ID - Dixon2006 ER - TY - JOUR AU - Gómez-Reino, J. J. AU - Carmona, L. AU - Valverde, V. R. PY - 2003 DA - 2003// TI - BIOBADASER group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report JO - Arthritis Rheum VL - 48 UR - https://doi.org/10.1002/art.11137 DO - 10.1002/art.11137 ID - Gómez-Reino2003 ER - TY - JOUR AU - Ritchlin, C. h. r. i. s. t. o. p. h. e. r. AU - Rahman, P. r. o. t. o. n. AU - Kavanaugh, A. r. t. h. u. r. AU - McInnes, I. a. i. n. B. AU - Puig, L. l. u. i. s. AU - Li, S. h. u. AU - Wang, Y. u. h. u. a. AU - Shen, Y. a. u. n. g. -. K. a. u. n. g. AU - Doyle, M. i. t. t. i. e. K. AU - Mendelsohn, A. l. a. n. M. AU - Gottlieb, A. l. i. c. e. B. PY - 2014 DA - 2014// TI - Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial JO - Annals of the Rheumatic Diseases VL - 73 UR - https://doi.org/10.1136/annrheumdis-2013-204655 DO - 10.1136/annrheumdis-2013-204655 ID - Ritchlin2014 ER - TY - STD TI - Mease PJ, van der Heijde D, Ritchlin CT, et al. SPIRIT-P1 Study Group. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naïve patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. Ann Rheum Dis. 2017;76:79–87. ID - ref24 ER - TY - JOUR AU - Nash, P. AU - Kirkham, B. AU - Okada, M. PY - 2017 DA - 2017// TI - SPIRIT-P2 study group. Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial JO - Lancet. VL - 389 UR - https://doi.org/10.1016/S0140-6736(17)31429-0 DO - 10.1016/S0140-6736(17)31429-0 ID - Nash2017 ER - TY - STD TI - Singh JA, Guvatt G, Ogdie A, et al. Special article: 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol. 2019;71:5–32. ID - ref26 ER -